Migraine Characteristics and Associated Factors
September 10, 2026 updated by: Demet Öztürk, Lokman Hekim University
Evaluation of Clinical Characteristics of Migraine and Associated Factors in Individuals Diagnosed With Primary Migraine
This cross-sectional study aims to evaluate the clinical characteristics of migraine and factors associated with migraine-related disability and impact in adults diagnosed with primary migraine.
Participants will complete questionnaires assessing sociodemographic and lifestyle characteristics, headache features, neck pain, sleep quality, fatigue, migraine-related disability, and the impact of headache on daily life.
Migraine-related disability will be assessed using the Migraine Disability Assessment Scale (MIDAS), and headache impact will be assessed using the Headache Impact Test-6 (HIT-6).
In addition, participants will undergo a physical examination including assessment of tender points.
The study will investigate the relationships between migraine-related outcomes and clinical and lifestyle factors.
No treatment or therapeutic intervention will be administered as part of the study.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Migraine is a common neurological condition that may substantially affect daily functioning, work or school performance, social participation, and quality of life. The burden of migraine may be influenced not only by headache intensity and frequency but also by associated clinical and lifestyle factors.
This cross-sectional study is designed to characterize migraine-related symptoms and to examine factors associated with migraine-related disability and headache impact in adults with a diagnosis of primary migraine. Data will be collected during a single face-to-face assessment. Participants will complete self-reported measures covering sociodemographic and lifestyle characteristics, headache features, associated symptoms, neck pain, perceived sleep quality, fatigue, migraine-related disability, and the impact of headache on daily life. A physical examination will also be performed to assess predefined tender points.
The study will explore the relationships between migraine-related outcomes and selected clinical and lifestyle characteristics. No therapeutic intervention will be administered, and participation will involve assessment procedures only.
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Demet Öztürk, Phd
- Phone Number: 05068394288
- Email: demett.ozturkk@gmail.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The study population will consist of adults aged 18 years or older who have been diagnosed with primary migraine by a neurologist.
Individuals who meet the study eligibility criteria and voluntarily agree to participate will be recruited through study announcements shared via social media platforms, including LinkedIn, WhatsApp, and Instagram.
Eligible participants will be invited to Lokman Hekim University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, where all study assessments will be conducted face to face.
The study population will include individuals with different clinical characteristics of migraine in order to evaluate migraine-related disability, headache impact, associated symptoms, lifestyle-related factors, and physical examination findings.
Description
Inclusion Criteria:
- Aged 18 years or older
- Diagnosed with primary migraine by a neurologist
- Having a history of migraine for at least 3 months
- Able to understand and complete the study questionnaires and assessments
- Willing to participate voluntarily in the study
Exclusion Criteria:
- Presence of a secondary headache disorder
- Presence of another neurological or systemic condition that may substantially affect headache characteristics or interfere with the study assessments
- Presence of a cognitive or communication impairment that prevents reliable completion of the questionnaires
- Incomplete completion of the study assessments or questionnaires
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Individuals With Primary Migraine
Adults diagnosed with primary migraine who meet the study eligibility criteria and undergo the study assessments, including questionnaires evaluating migraine characteristics, migraine-related disability, headache impact, neck pain, sleep quality, fatigue, and lifestyle-related factors, as well as tender point examination.
No therapeutic intervention will be administered.
|
Participants completed assessment form.
No intervention was administered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Migraine-Related Disability
Time Frame: Baseline
|
Migraine-related disability will be assessed using the Migraine Disability Assessment Scale (MIDAS).
The MIDAS consists of five items evaluating the number of days over the previous 3 months in which headache caused missed or substantially reduced productivity in work/school, household activities, and family/social/leisure activities.
The total score is calculated by summing the number of days reported across the five items, with higher scores indicating greater migraine-related disability.
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Headache Impact
Time Frame: Baseline
|
Headache impact will be assessed using the Headache Impact Test-6 (HIT-6).
The HIT-6 consists of six items evaluating the impact of headache on daily activities, fatigue, emotional well-being, and concentration.
The total score ranges from 36 to 78, with higher scores indicating a greater impact of headache on daily life.
|
Baseline
|
|
Headache Pain Intensity
Time Frame: Baseline
|
Headache pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates unbearable pain.
Higher scores indicate greater headache intensity.
|
Baseline
|
|
Neck Pain Intensity
Time Frame: Baseline
|
Neck pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates unbearable pain.
Higher scores indicate greater neck pain intensity.
|
Baseline
|
|
Perceived Sleep Quality
Time Frame: Baseline
|
Perceived sleep quality will be assessed using a 10-cm Visual Analog Scale.
Participants will rate their sleep quality from 0 to 10, with higher scores indicating better perceived sleep quality.
|
Baseline
|
|
Daily Step Count
Time Frame: Baseline
|
Daily physical activity will be represented by the participant's average daily step count obtained from personal devices such as smartphones or wearable activity trackers.
|
Baseline
|
|
Presence of Associated Migraine Symptoms
Time Frame: Baseline
|
The presence of migraine-associated symptoms, including nausea, vomiting, photophobia, phonophobia, osmophobia, dizziness, and imbalance, will be recorded based on participant self-report.
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 1, 2026
Primary Completion (Estimated)
November 1, 2026
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
September 10, 2026
First Submitted That Met QC Criteria
September 10, 2026
First Posted (Actual)
September 16, 2026
Study Record Updates
Last Update Posted (Actual)
September 16, 2026
Last Update Submitted That Met QC Criteria
September 10, 2026
Last Verified
September 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2026-BA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.